Effect of interleukin 6 blockers on body composition, adipocytokines and insulin-like growth factor 1 in patients with rheumatoid arthritis

Effect of interleukin 6 blockers on body composition, adipocytokines and insulin-like growth factor 1 in patients with rheumatoid arthritis

The aim – to study the effect of interleukin (IL) 6 blockers on body composition, as well as leptin, adiponectin, and insulin-like growth factor (IGF) 1 levels in patients with rheumatoid arthritis (RA) during a prospective follow-up of 6 months.Material and methods. The study included 29 patients w...

Full description

Saved in:

Bibliographic Details
Main Authors:	L. V. Kondratyeva, Yu. N. Gorbunova, T. V. Popkova, A. A. Abramkin, T. A. Lisitsyna, N. V. Demin, M. E. Diatroptov, A. S. Avdeeva
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2025-07-01
Series:	Научно-практическая ревматология
Subjects:	interleukin 6 blockers tocilizumab olokizumab body composition adipocytokines leptin adiponectin insulin-like growth factor 1
Online Access:	https://rsp.mediar-press.net/rsp/article/view/3763
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Blockade of the interleukin-6 signaling pathway in rheumatoid arthritis: Effects on obesity, adipocytokines and glucose metabolism
by: L. V. Kondratyeva, et al.
Published: (2024-01-01)

Association of Adipocytokines and Vitamin D Status in Tuberculosis
by: Hazhar M. Balaky, et al.
Published: (2023-10-01)

Evaluation of Adipocytokines Level in Newly Diagnosed Hypothyroid Patients
by: Indrajeet Yadav, et al.
Published: (2025-05-01)

The role of Adipocytokines, Vitamin D, and C in Colorectal Cancer
by: Akam Jasim Mustafa, et al.
Published: (2023-06-01)

Adipocytokines in early rheumatoid arthritis: relationship to pro- and anti-inflammatory markers
by: L. V. Kondratyeva, et al.
Published: (2019-01-01)

Cross-Sectional Analysis of IL-6, TNF-α, Adiponectin, Leptin, and Klotho Serum Levels in Relation to BMI Among Overweight and Obese Children Aged 10–14 in La Rioja, Spain
by: Beatriz Fernández-Vallejo, et al.
Published: (2025-01-01)

Adipocytokine Protein Expression from Visceral Fat Differs Significantly Based on Diet, Sex, and Age in C3H/HeJ Mice Fed Long-Term, High-Fat Diets, ± Ammonium-Hydroxide-Supplemented Dietary Protein
by: Caleb Boren, et al.
Published: (2025-03-01)

The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)
by: E. L. Nasonov, et al.
Published: (2022-11-01)

Associations of adipocytokine expression and cardiovascular risk factors in stable coronary artery disease
by: E. V. Belik, et al.
Published: (2021-04-01)

Olokizumab in patients with inflammatory phenotype of osteoarthritis, treatment experience
by: A. M. Lila, et al.
Published: (2024-06-01)

Adipokines and personal anxiety in individuals aged 25-44 years
by: V. V. Gafarov, et al.
Published: (2025-07-01)

Efficacy of olokizumab against comorbid depressive disorder in patients with rheumatoid arthritis: Preliminary results of the study
by: T. A. Lisitsyna, et al.
Published: (2023-04-01)

Physiological and Immunological Disturbance in Rheumatoid Arthritis Patients
by: Firas Faris Rija, et al.
Published: (2021-06-01)

Risk of secondary bacterial infections during treatment with anti-inflammatory genetically engineered biological drugs in COVID-19 patients
by: V. I. Petrov, et al.
Published: (2025-03-01)

Clinical case of olokizumab treatment in a patient with diffuse systemic sclerosis
by: E. S. Kuvardin, et al.
Published: (2022-11-01)

Evaluation of the economic effect of biological therapy in patients with severe COVID-19 and cytokine storm
by: M. Yu. Frolov, et al.
Published: (2021-02-01)

Obesity and breast cancer: Association of serum adiponectin, leptin, and adiponectin–leptin ratio as risk biomarkers
by: Madhav Danthala, et al.
Published: (2018-01-01)

Experience of using the interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis in real-life clinical practice (based on data from Tyumen Regional Rheumatology Center)
by: I. M. Patrikeeva, et al.
Published: (2025-02-01)

Exploring the Relationship Between Adipocytokines and Endometrial Cancer: Identifying Correlations With Clinico‐Pathological Prognostic Factors
by: Irene Ray, et al.
Published: (2025-07-01)

Prospective changes in lipocalin-2 and adipocytokines among adults with obesity
by: Mohammed S. Daoud, et al.
Published: (2025-08-01)

EXPERIENCE WITH TOCILIZUMAB, AN INTERLEUKIN 6 INHIBITOR, USED FOR THE TREATMENT OF GIANT CELL ARTERITIS WITH SEVERE COMORBIDITY
by: T. V. Beketova, et al.
Published: (2018-05-01)

Rheumatoid Arthritis: Clinical-Laboratory and Ultrasound Parallels
by: I. A. Krivotulova, et al.
Published: (2021-08-01)

INHIBITION OF INTERLEUKIN 6 IN IMMUNE INFLAMMATORY RHEUMATIC DISEASES: ACHIEVEMENTS, PROSPECTS, AND HOPES
by: E. L. Nasonov, et al.
Published: (2018-01-01)

ADIPOKINES AS MODIFIABLE RISK FACTORS OF CARDIOVASCULAR DISEASE
by: N. G. Veselovskaya, et al.
Published: (2010-12-01)

Levels of Leptin, Adiponectin, and Insulin in COVID-19 Patients
by: Sura Zahim HUSSEIN, et al.
Published: (2022-03-01)

Lower BMI in Tanzanian Adults with 'Schistosoma mansoni' Infection is Not Explained by Differences in Serum Adipocytokine Levels
by: Khanh Pham, et al.
Published: (2025-06-01)

Efficacy of olocizumab in treatment of COVID-19 patients
by: T. V. Goma, et al.
Published: (2022-12-01)

Switching from interleukin-6 receptor inhibitors to the direct interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis: efficacy and safety during one year of therapy
by: P. A. Shesternya, et al.
Published: (2024-10-01)

INNOVATIVE TREATMENTS FOR TAKAYASU’S ARTERITIS: A FOCUS ON INTERLEUKIN-6 INHIBITORS. THE AUTHORS’ EXPERIENCE WITH TOCILIZUMAB AND A REVIEW OF LITERATURE
by: T. V. Beketova, et al.
Published: (2017-10-01)

The efficacy of interleukin-6 inhibitor tocilizumab for takayasu’s arteritis, after insufficient response to previous treatment with glucocorticoids, methotrexate, cyclophosphamide, fludarabine. (A case report)
by: V. N. Antipova, et al.
Published: (2021-01-01)

Study the levels of Leptin, and Adiponectin with Paraoxonase in Obese Individuals (male & female)
by: Entedhar R. Sarhat
Published: (2023-02-01)

Adiposity: A Seed of Depression
by: Dhivya Selvaraj, et al.
Published: (2024-04-01)

LEPTIN AND ADIPONECTIN CONTENT IN BLOOD SERUM AND RECEPTOR EXPRESSION IN OSTEOPENIA AND OSTEOPOROSIS IN PATIENTS SUFFERING FROM CHRONIC OBSTRUCTIVE PULMONARY DISEASE
by: L. G. Ugay, et al.
Published: (2015-10-01)

Role of interleukin-6 in the development of atherosclerosis in rheumatoid arthritis
by: Elena Vasilyevna Udachkina, et al.
Published: (2013-10-01)

Effects of Extracted Phenolic Compounds from Grape Seeds on Leptin, Adiponectin and Resistin Levels in Rats Fed with High Fat Foods
by: Entedhar Rifaat Sarhat, et al.
Published: (2018-04-01)

The Effect of Kidney Transplantation and Immunosuppressive Therapy on Adipose Tissue Content and Adipocytokine Plasma Concentration—Preliminary Study
by: Daria Śleboda-Taront, et al.
Published: (2025-04-01)

Efficacy and safety of olokizumab in the treatment of rheumatoid arthritis in real-world clinical practice in Kazakhstan
by: G. A. Togizbayev, et al.
Published: (2025-06-01)

Pharmacotherapy of giant cell arteritis and polymyalgia rheumatica: Prospects for the use of monoclonal antibodies to interleukin 6
by: Evgeny L. Nasonov, et al.
Published: (2024-09-01)

The role of peptide hormones (adiponectin, leptin, insulin) in the pathogenesis of atherosclerosis
by: S. A. Smetnev, et al.
Published: (2015-11-01)

The association between serum leptin, adiponectin and resistin levels with chronic kidney disease with and without hemodialysis patients
by: Maha Elttayef Jasim, et al.
Published: (2025-06-01)